Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Revenue (2016 - 2025)

Historic Revenue for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to $249.7 million.

  • Ascendis Pharma A's Revenue rose 29322.44% to $249.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $866.1 million, marking a year-over-year increase of 6275.13%. This contributed to the annual value of $439.2 million for FY2024, which is 3484.54% up from last year.
  • Ascendis Pharma A's Revenue amounted to $249.7 million in Q3 2025, which was up 29322.44% from $178.9 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Revenue registered a high of $331.2 million during Q4 2024, and its lowest value of $899852.1 during Q1 2021.
  • In the last 5 years, Ascendis Pharma A's Revenue had a median value of $51.6 million in 2023 and averaged $89.1 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Revenue crashed by 7629.3% in 2022, and later skyrocketed by 129434.92% in 2023.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Revenue stood at $98.5 million in 2021, then tumbled by 76.29% to $23.4 million in 2022, then soared by 1294.35% to $325.7 million in 2023, then rose by 1.7% to $331.2 million in 2024, then dropped by 24.6% to $249.7 million in 2025.
  • Its Revenue was $249.7 million in Q3 2025, compared to $178.9 million in Q2 2025 and $106.2 million in Q1 2025.